Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models

Nature Medicine

Volumn 22, Issue 10, 2016, Pages 1108-1119

  Svensson, Robert U ^a   Parker, Seth J ^b   Eichner, Lillian J ^a   Kolar, Matthew J ^a   Wallace, Martina ^b   Brun, Sonja N ^a   Lombardo, Portia S ^a   Van Nostrand, Jeanine L ^a   Hutchins, Amanda ^a   Vera, Lilliana ^a   Gerken, Laurie ^a   Greenwood, Jeremy ^c   Bhat, Sathesh ^c   Harriman, Geraldine ^d   Westlin, William F ^d   Harwood, H James ^d   Saghatelian, Alan ^a   Kapeller, Rosana ^d   Metallo, Christian M ^b,e   Shaw, Reuben J ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c SCHRÖDINGER INC   (United States)

^d Nimbus Therapeutics   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ACETYL COENZYME A CARBOXYLASE INHIBITOR; ANTINEOPLASTIC AGENT; CARBOPLATIN; K RAS PROTEIN; ND 646; UNCLASSIFIED DRUG; ACACB PROTEIN, HUMAN; ACACB PROTEIN, MOUSE; ACYLTRANSFERASE; AMINOGLYCOSIDE N1-ACETYLTRANSFERASE; ENZYME INHIBITOR; FATTY ACID; KRAS2 PROTEIN, MOUSE; ND-646; PROTEIN P21; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; PYRIMIDINONE DERIVATIVE; STK11 PROTEIN, MOUSE; THIOPHENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; DIMERIZATION; ENZYME INHIBITION; EXPERIMENTAL MODEL; FATTY ACID SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; ALLOSTERISM; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENETICS; KNOCKOUT MOUSE; LIPID METABOLISM; LUNG NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY;

ACETYL-COA CARBOXYLASE; ACETYLTRANSFERASES; ALLOSTERIC REGULATION; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; ENZYME INHIBITORS; FATTY ACIDS; HUMANS; LIPID METABOLISM; LUNG NEOPLASMS; MICE; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS P21(RAS); PYRIMIDINONES; THIOPHENES; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84988411272     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4181     Document Type: Article

References (42)

1. Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033 (2009).
2. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
3. Kuhajda, F. P. Fatty acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 16, 202-208 (2000).
4. Menendez, J. A. & Lupu, R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 7, 763-777 (2007).
5. Currie, E., Schulze, A., Zechner, R., Walther, T. C. & Farese, R. V. Jr. Cellular fatty acid metabolism and cancer. Cell Metab. 18, 153-161 (2013).
6. Wakil, S. J. & Abu-Elheiga, L. A. Fatty acid metabolism: target for metabolic syndrome. J. Lipid Res. 50, S138-S143 (2009).
7. McGarry, J. D., Leatherman, G. F. & Foster, D. W. Carnitine palmitoyltransferase I. The site of inhibition of hepatic fatty acid oxidation by malonyl-CoA. J. Biol. Chem. 253, 4128-4136 (1978).
8. Zhang, F. & Du, G. Dysregulated lipid metabolism in cancer. World J. Biol. Chem. 3, 167-174 (2012).
9. Steinberg, G. R. & Kemp, B. E. AMPK in health and disease. Physiol. Rev. 89, 1025-1078 (2009).
10. Fogarty, S. & Hardie, D. G. Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim. Biophys. Acta 1804, 581-591 (2010).
11. Swinnen, J. V. et al. Mimicry of a cellular low-energy status blocks tumor cell anabolism and suppresses the malignant phenotype. Cancer Res. 65, 2441-2448 (2005).
12. Zadra, G. et al. A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis. EMBO Mol. Med. 6, 519-538 (2014).
13. O'Brien, A. J. et al. Salicylate activates AMPK and synergizes with metformin to reduce the survival of prostate and lung cancer cells ex vivo through inhibition of de novo lipogenesis. Biochem. J. 469, 177-187 (2015).
14. Fullerton, M. D. et al. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat. Med. 19, 1649-1654 (2013).
15. Brusselmans, K., De Schrijver, E., Verhoeven, G. & Swinnen, J. V. RNA-interference-mediated silencing of the acetyl-CoA carboxylase alpha gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res. 65, 6719-6725 (2005).
16. Chajès, V., Cambot, M., Moreau, K., Lenoir, G. M. & Joulin, V. Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival. Cancer Res. 66, 5287-5294 (2006).
17. Beckers, A. et al. Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res. 67, 8180-8187 (2007).
18. Tong, L. & Harwood, H. J. Jr. Acetyl-coenzyme A carboxylases: versatile targets for drug discovery. J. Cell. Biochem. 99, 1476-1488 (2006).
19. Harriman, G. et al. Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity and modulates dyslipidemia in rats. Proc. Natl. Acad. Sci. USA 113, E1796-E1805 (2016).
20. Savage, D. B. et al. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J. Clin. Invest. 116, 817-824 (2006).
21. Harada, N. et al. Hepatic de novo lipogenesis is present in liver-specific ACC1-deficient mice. Mol. Cell. Biol. 27, 1881-1888 (2007).
22. Gandhi, L. et al. Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis. Cancer Prev. Res. (Phila.) 2, 330-337 (2009).
23. Zinszner, H. et al. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev. 12, 982-995 (1998).
24. Little, J. L., Wheeler, F. B., Fels, D. R., Koumenis, C. & Kridel, S. J. Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells. Cancer Res. 67, 1262-1269 (2007).
25. Cho, Y. S. et al. Molecular mechanism for the regulation of human ACC2 through phosphorylation by AMPK. Biochem. Biophys. Res. Commun. 391, 187-192 (2010).
26. Shen, Y., Volrath, S. L., Weatherly, S. C., Elich, T. D. & Tong, L. A mechanism for the potent inhibition of eukaryotic acetyl-coenzyme A carboxylase by soraphen A, a macrocyclic polyketide natural product. Mol. Cell 16, 881-891 (2004).
27. Wei, J. & Tong, L. Crystal structure of the 500-kDa yeast acetyl-CoA carboxylase holoenzyme dimer. Nature 526, 723-727 (2015).
28. Munday, M. R., Campbell, D. G., Carling, D. & Hardie, D. G. Identification by amino acid sequencing of three major regulatory phosphorylation sites on rat acetyl-CoA carboxylase. Eur. J. Biochem. 175, 331-338 (1988).
29. Lee, W. N., Bassilian, S., Lim, S. & Boros, L. G. Loss of regulation of lipogenesis in the Zucker diabetic (ZDF) rat. Am. J. Physiol. Endocrinol. Metab. 279, E425-E432 (2000).
30. Shackelford, D. B. et al. LKB1 inactivation dictates therapeutic response of non-small-cell lung cancer to the metabolism drug phenformin. Cancer Cell 23, 143-158 (2013).
31. Jeon, S. M., Chandel, N. S. & Hay, N. AMPK regulates NADPH homeostasis to promote tumor cell survival during energy stress. Nature 485, 661-665 (2012).
32. Wang, C. et al. Acetyl-CoA carboxylase alpha inhibitor TOFA induces human cancer cell apoptosis. Biochem. Biophys. Res. Commun. 385, 302-306 (2009).
33. Camarda, R. et al. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat. Med. 22, 427-432 (2016).
34. Harriman, G. C., Masse, C. E., Harwood, H. J. Jr., Baht, S. & Greenwood, J. R. ACC inhibitors and uses thereof. US patent 8, 969, 557 (2015).
35. Metallo, C. M. et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481, 380-384 (2011).
36. Lewis, C. A. et al. Tracing compartmentalized NADPH metabolism in the cytosol and mitochondria of mammalian cells. Mol. Cell 55, 253-263 (2014).
37. Fernandez, C. A., Des Rosiers, C., Previs, S. F., David, F. & Brunengraber, H. Correction of 13C mass isotopomer distributions for natural stable isotope abundance. J. Mass Spectrom. 31, 255-262 (1996).
38. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281-2308 (2013).
39. Ran, F. A. et al. Double nicking by RNA-guided CRISPR-Cas9 for enhanced genome-editing specificity. Cell 154, 1380-1389 (2013).
40. McCabe, D. C., Rajakumar, B., Marshall, P., Smith, I. W. & Ravishankara, A. R. The relaxation of OH (v = 1) and OD (v = 1) by H2O and D2O at temperatures from 251 to 390 K. Phys. Chem. Chem. Phys. 8, 4563-4574 (2006).
41. Yang, D. et al. Assay of low deuterium enrichment of water by isotopic exchange with [U-13C3]acetone and gas chromatography-mass spectrometry. Anal. Biochem. 258, 315-321 (1998).
42. Lee, W. N. et al. In vivo measurement of fatty acids and cholesterol synthesis using D2O and mass isotopomer analysis. Am. J. Physiol. 266, E699-E708 (1994).